Trial Profile
A randomized phase I study of two different schedules of BAY 43-9006 [sorafenib] in patients with acute myeloid leukemia or myelodysplastic syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2010
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Feb 2010 Results published in Leukemia and Lymphoma.
- 10 Feb 2006 New trial record.